Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedAug 27, 2026
DataAggregated Company Financials
Companies47
  • 7D-0.1%
  • 3M0.9%
  • 1Y21.2%
  • YTD17.9%

The Biotech industry is up 1.9% in the last week, with Vitrolife up 6.0%. In the last 12 months, the industry was up 24%. Looking forward, earnings are forecast to grow by 34% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 27 Aug 2026SEK 250.9bSEK 40.1b-SEK 5,671,525,512.5633.6x-44.2x6.3x
Sat, 25 Jul 2026SEK 244.3bSEK 40.1b-SEK 5,681,898,890.0633.7x-43x6.1x
Mon, 22 Jun 2026SEK 239.2bSEK 38.4b-SEK 6,192,232,739.7436x-38.6x6.2x
Wed, 20 May 2026SEK 246.0bSEK 39.2b-SEK 5,347,839,383.8327.5x-46x6.3x
Fri, 17 Apr 2026SEK 238.9bSEK 38.5b-SEK 5,607,689,309.7718.1x-42.6x6.2x
Sun, 15 Mar 2026SEK 216.1bSEK 38.5b-SEK 5,720,272,654.2617.1x-37.8x5.6x
Tue, 10 Feb 2026SEK 225.2bSEK 38.6b-SEK 5,517,331,643.3728.8x-40.8x5.8x
Thu, 08 Jan 2026SEK 211.6bSEK 38.1b-SEK 556,322,323.0034x-380.3x5.6x
Sat, 06 Dec 2025SEK 209.4bSEK 38.1b-SEK 603,799,266.0431.5x-346.9x5.5x
Mon, 03 Nov 2025SEK 206.4bSEK 37.3b-SEK 1,210,338,400.4338.8x-170.5x5.5x
Wed, 01 Oct 2025SEK 199.2bSEK 36.4bSEK 3.0b31.3x65.8x5.5x
Fri, 29 Aug 2025SEK 204.0bSEK 36.0bSEK 2.9b33.9x71.4x5.7x
Sun, 27 Jul 2025SEK 192.9bSEK 35.9bSEK 2.8b28.7x69.1x5.4x
Tue, 24 Jun 2025SEK 178.9bSEK 35.2bSEK 2.2b28.1x80.3x5.1x
Thu, 22 May 2025SEK 195.2bSEK 33.9bSEK 1.2b34x162.4x5.8x
Sat, 19 Apr 2025SEK 175.2bSEK 33.7bSEK 758.0m29x231.2x5.2x
Mon, 17 Mar 2025SEK 196.7bSEK 33.7bSEK 579.2m33.2x339.6x5.8x
Wed, 12 Feb 2025SEK 217.0bSEK 33.7bSEK 360.6m52.9x601.7x6.4x
Fri, 10 Jan 2025SEK 217.8bSEK 33.0b-SEK 4,418,458,844.01150.4x-49.3x6.6x
Sun, 08 Dec 2024SEK 214.0bSEK 33.0b-SEK 4,445,850,513.32146.4x-48.1x6.5x
Tue, 05 Nov 2024SEK 218.1bSEK 33.2b-SEK 4,482,242,588.44136.1x-48.7x6.6x
Thu, 03 Oct 2024SEK 210.4bSEK 31.4b-SEK 5,523,741,940.7849.5x-38.1x6.7x
Sat, 31 Aug 2024SEK 216.4bSEK 31.4b-SEK 5,530,209,354.7351.1x-39.1x6.9x
Mon, 29 Jul 2024SEK 205.1bSEK 31.4b-SEK 5,422,714,425.0246.9x-37.8x6.5x
Wed, 26 Jun 2024SEK 196.7bSEK 30.6b-SEK 5,517,165,724.6539.2x-35.7x6.4x
Fri, 24 May 2024SEK 192.4bSEK 30.6b-SEK 5,401,683,980.7139.6x-35.6x6.3x
Sun, 21 Apr 2024SEK 178.5bSEK 29.8b-SEK 5,265,765,392.2366.1x-33.9x6x
Tue, 19 Mar 2024SEK 184.5bSEK 29.8b-SEK 5,637,407,911.1159.3x-32.7x6.2x
Thu, 15 Feb 2024SEK 175.6bSEK 29.6b-SEK 5,684,331,437.9662.6x-30.9x5.9x
Sat, 13 Jan 2024SEK 190.3bSEK 28.7b-SEK 1,198,820,921.0060.5x-158.8x6.6x
Mon, 11 Dec 2023SEK 169.9bSEK 28.7b-SEK 1,200,221,950.0058.4x-141.6x5.9x
Wed, 08 Nov 2023SEK 157.7bSEK 28.6b-SEK 1,293,048,329.0049.4x-122x5.5x
Fri, 06 Oct 2023SEK 157.5bSEK 27.4b-SEK 2,017,186,235.0048.4x-78.1x5.8x
Sun, 03 Sep 2023SEK 155.4bSEK 27.3b-SEK 1,924,351,833.0052.5x-80.8x5.7x
Price to Earnings Ratio

-80.8x


Total Market Cap: SEK 155.4bTotal Earnings: -SEK 1,924,351,833.00Total Revenue: SEK 27.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -38.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 14% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market2.16%
Healthcare0.12%
Biotech-0.14%
Biotech-0.14%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VITR VitrolifeSEK 95.056.0%
+SEK 724.5m		-29.2%PS3.8x
EGTX Egetis TherapeuticsSEK 8.0015.3%
+SEK 492.8m		54.7%PS56.4x
MVIR MedivirSEK 2.0320.1%
+SEK 210.1m		2.4%PS144.1x
HNSA Hansa BiopharmaSEK 43.043.2%
+SEK 136.4m		36.4%PS23.1x
BONEX Bonesupport HoldingSEK 228.200.9%
+SEK 131.7m		-22.6%PE70.3x

Latest News

MVIR
SEK 2.03
Medivir
7D
20.1%
1Y
2.4%
Narrative Update • Aug 25

MVIR: Extended Patent Protection Will Support Future Liver Cancer Opportunity

The latest narrative update on Medivir reflects a higher analyst fair value estimate of SEK 4.60 per share from SEK 4.00, with analysts pointing to changes in discount rate assumptions, a lower revenue growth outlook, a slightly stronger profit margin view, and a much higher future P/E estimate as key drivers behind the revised target. What’s in the News for Medivir Medivir received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering the combination of fostroxacitabine bralpamide (fostrox) with lenvatinib for hepatocellular carcinoma and liver metastases, with expected protection and market exclusivity until at least April 2041.
SYNACT
SEK 19.02
SynAct Pharma
7D
-11.3%
1Y
5.7%
VICO
SEK 10.66
Vicore Pharma Holding
7D
-4.1%
1Y
-1.3%
EGTX
SEK 8.00
Egetis Therapeutics
7D
15.3%
1Y
54.7%
CANTA
SEK 1.96
Cantargia
7D
12.1%
1Y
-26.7%
Narrative Update • Aug 20

CANTA: Equity Raise Will Support Advancing High-Risk MDS Opportunity

Analysts have cut their SEK fair value estimate for Cantargia from SEK 6.00 to SEK 4.50. This reflects updated assumptions for weaker revenue growth, a higher discount rate and a less favourable future P/E, which are partly offset by slightly stronger projected profit margins.
BIOA B
SEK 322.00
BioArctic
7D
-2.8%
1Y
16.5%
SOBI
SEK 464.20
Swedish Orphan Biovitrum
7D
-0.3%
1Y
58.6%
Narrative Update • Aug 18

SOBI: Execution Risks Will Test Confidence In Elevated Margin Assumptions

The analyst price target for Swedish Orphan Biovitrum has been raised from SEK 315.00 to SEK 375.50. Analysts point to higher assumed revenue growth and profit margins, refreshed Street targets in the SEK 475 to SEK 575 range, and updated P/E expectations as key drivers of the revision.
VITR
SEK 95.05
Vitrolife
7D
6.0%
1Y
-29.2%
Narrative Update • Aug 12

VITR: CEO Transition And Higher Margin Outlook Will Support Future Upside

Analysts have reset their price target for Vitrolife from SEK 215 to SEK 155. They adjusted assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple in their updated models.
HNSA
SEK 43.04
Hansa Biopharma
7D
3.2%
1Y
36.4%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
BINV
SEK 23.50
BioInvent International
7D
-1.9%
1Y
-26.8%
CURAS
DKK 15.25
Curasight
7D
-7.6%
1Y
269.2%
BIOG B
SEK 115.50
BioGaia
7D
0.4%
1Y
10.5%
Narrative Update • Jul 21

BIOG B: Dividend Power And Skincare Expansion Will Support Future Rerating

Analysts have trimmed their price target on BioGaia to SEK 152.50 from SEK 165.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News BioGaia New Sciences AB expanded the BioGaia Skincare portfolio with two new products, Gentle Balm to Milk Wash and Soothing Face & Body Lotion, and introduced an updated design across the full range, targeting babies and children with dry, sensitive and atopic prone skin.
BONEX
SEK 228.20
Bonesupport Holding
7D
0.9%
1Y
-22.6%
Narrative Update • Jul 20

BONEX: Share Buybacks Will Support Bullish Case Despite Lowered Growth Assumptions

Analysts have reduced their price target for Bonesupport Holding to SEK275 from SEK310, reflecting updated assumptions around a slightly higher discount rate, more moderate revenue growth, a marginally stronger profit margin, and a lower future P/E multiple. What's in the News for Bonesupport Holding Bonesupport Holding AB (publ) plans to commence a share repurchase program on June 9, 2026, following a mandate from the Annual General Meeting on May 12, 2026.
CRNO B
SEK 4.52
Cereno Scientific
7D
-3.7%
1Y
-54.7%
SANION
SEK 11.82
Saniona
7D
-6.2%
1Y
-11.5%